Retatrutide, a novel dual activator of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) binding site , is showing promising results in initial human trials . Recent examination https://apollobookmarks.com/story21302987/retatrutide-emerging-investigations-and-potential-therapeutic-roles